Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zatrik ORS is a combination product manufactured by Tabros Pharma, typically used for the management of infectious diarrhea and associated dehydration. It contains **azithromycin**, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of susceptible microorganisms, and **oral rehydration salts (ORS)**, which are used to prevent or treat fluid loss. The ORS component utilizes the sodium-glucose cotransporter 1 (SGLT1) in the small intestine to optimize the absorption of water and electrolytes. While the provided context lists 'Zatrik ORS' as a single formulation, it appears to be a concatenation of two separate Tabros products: the antibiotic Zatrik and the rehydration salt Tab-ORS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azithromycin + oral rehydration salts.